# The missing metric in medical weight loss: why preserving muscle matters Canonical HTML source: [https://drluhard.com/insight-preserving-muscle-during-medical-weight-loss.html](https://drluhard.com/insight-preserving-muscle-during-medical-weight-loss.html) - Author: Dr Luhard Jansen van Vuuren, MBChB (Pret) - Published: 1 October 2026 - Updated: 1 October 2026 - Topic: Body composition and medically assisted weight loss A lower number on the scale can be meaningful, but it does not describe what was lost. Responsible treatment also considers fat mass, lean tissue, nutrition, strength and day-to-day function. ## The short answer Effective weight loss usually includes loss of both fat mass and some lean mass. The aim is not to promise zero lean-mass change. It is to make fat loss the dominant change while supporting adequate nutrition, progressive resistance exercise and clinically appropriate monitoring. ## Why scale weight is incomplete Two people can lose the same number of kilograms and have very different outcomes. One may improve waist circumference, blood pressure, glucose control and mobility while maintaining strength. Another may eat too little, become weaker and struggle to meet protein and micronutrient needs. Good follow-up asks more than how much weight was lost. It also asks how the patient is eating, moving, sleeping and functioning; whether side effects are limiting intake; and whether the pace of change remains appropriate. ## Lean mass is not the same as muscle Body-composition methods generally classify fat mass and fat-free or lean mass. The lean compartment also includes body water, organs, bone and other tissues. A change reported as lean-mass loss should therefore not automatically be described as the same amount of skeletal-muscle loss. DXA, bioelectrical impedance and other methods estimate body compartments differently. Hydration, glycogen, recent food, exercise and testing conditions can influence results. Trends are most useful when measured consistently and interpreted alongside strength and function. ## What the evidence shows In the DXA substudy of the SURMOUNT-1 trial, 160 participants had measurements at baseline and 72 weeks. With tirzepatide, average fat-mass reduction was substantially greater than average lean-mass reduction; approximately three quarters of the weight lost was fat mass and one quarter was lean mass. This was a substudy average, not a prediction for every patient, and lean mass is not identical to skeletal muscle. The 2026 American Diabetes Association obesity standards note that lean mass commonly falls during meaningful weight reduction, while physical function can still improve. They recommend attention to nutrition, adequate protein and muscle-strengthening activity, tailored to the patient. The responsible message is neither that medicine destroys muscle nor that muscle does not matter. Substantial weight loss changes body composition. Clinicians should anticipate that change and manage the modifiable factors around it. ## Who may need closer attention? Monitoring becomes especially important when a patient is older, has low baseline strength or mobility, has experienced previous frailty, is losing weight very rapidly, has persistent nausea or vomiting, follows a highly restrictive diet, or lives with a condition that affects nutrition or exercise capacity. These factors do not automatically exclude treatment. They make individualisation and, where appropriate, input from a dietitian, physiotherapist, biokineticist or another relevant professional more important. ## Protein: necessary, but not a universal number There is no single protein target for every patient. Needs depend on body size, age, activity, total energy intake, dietary pattern, treatment response and medical conditions. Kidney disease and other clinical factors may materially change what is appropriate. ## Resistance exercise belongs in the conversation Aerobic activity is valuable for cardiovascular health and fitness. Muscle-strengthening exercise adds a different signal by asking the body to maintain and adapt muscle tissue. The programme should be progressive, realistic and matched to the patient's starting ability, injuries and medical status. ## Useful monitoring Depending on the clinical question, follow-up may include: - weight trajectory and waist circumference; - dietary intake, protein adequacy, hydration and treatment tolerance; - strength, mobility and day-to-day function; - body-composition trends where the result will change care; - blood pressure, glucose markers and other metabolic outcomes; - laboratory assessment when symptoms, medicines or nutritional risk make it relevant. A measurement earns its place when it can change the treatment plan. More data is not automatically better care. ## An assessment-first plan 1. Establish baseline health, eating pattern, activity, strength and risk factors. 2. Set outcomes beyond kilograms, including metabolic health and function. 3. Choose evidence-based treatment with realistic expectations. 4. Plan nutrition and resistance exercise from the start. 5. Review tolerance, rate of loss, intake, strength and clinically relevant measurements. 6. Adjust the dose, pace, nutrition, activity or wider plan when the evidence from that patient requires it. [Explore Dr Luhard's medical weight-loss approach](https://drluhard.com/medical-weight-loss-pretoria.html). ## Frequently asked questions ### Do GLP-1 medicines cause muscle loss? Weight loss from any effective intervention can include some lean mass as well as fat mass. Lean mass is not identical to skeletal muscle, and study averages do not predict one person's result. Nutrition, resistance exercise, health status and monitoring all matter. ### How much protein do I need? There is no single safe target for everyone. It should be individualised for body size, age, activity, intake, treatment response and conditions such as kidney disease. ### Is a body-composition scan essential? No. It can add useful trend information when interpreted consistently, but hydration and measurement method affect estimates. Strength, function, waist, nutrition and clinical progress may also be important. ### Where can I consult Dr Luhard? Dr Luhard consults through Medify at 265 Main Street, Waterkloof, Pretoria. [Request a consultation on WhatsApp](https://wa.me/27655595412). ## Sources - [American Diabetes Association: Pharmacologic Treatment of Obesity in Adults—2026 Standards of Care](https://doi.org/10.2337/dci25-0008) - [Look M, et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1](https://pubmed.ncbi.nlm.nih.gov/39996356/) - [World Health Organization: global guideline on GLP-1 medicines for obesity](https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity) ## Medical disclaimer This article provides general medical information and does not replace an individual consultation, diagnosis, dietary prescription or exercise clearance. Treatment suitability and monitoring must be determined for the individual patient.